ARDX

NEW YORK, Nov. 06, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ardelyx, Inc. (NASDAQ: ARDX) between January 13, 2025 and August 6, 2026, inclusive (the “Class Period”), of the important November 16, 2026 lead plaintiff deadline.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Ardelyx to Contact Him Directly to Discuss Their Options New York, New York--(Newsfile Corp. - November 6, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the November 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX). [You may also click here for additional information] WHY: Faruqi & Faruqi, LLP, a leading national securities law firm, informs investors of the federal securities class action on behalf of all investors who purchased or otherwise acquired Ardelyx common stock between January 13, 2025, and August 6, 2026, inclusive (the "Class Period").

New class action for Ardelyx, Inc. (ARDX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/16/2026

Important Notice Regarding Alleged Payer Access and Reimbursement Misrepresentations: the lawsuit contends Ardelyx pointed investors toward $1.75 billion in combined peak sales while payer utilization-management barriers were allegedly restricting patient starts for IBSRELA and XPHOZAH. NEW YORK, Nov. 5, 2026 /PRNewswire/ -- SueWallSt notifies investors in Ardelyx, Inc. (NASDAQ: ARDX) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between January 13, 2025 and August 6, 2026.

LOS ANGELES, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ARDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

NEW YORK, Nov. 5, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ardelyx, Inc. ("Ardelyx" or "the Company") (NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ARDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ardelyx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ardelyx between January 13, 2025 and August 6, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 4, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardelyx, Inc. ("Ardelyx" or the "Company") (NASDAQ: ARDX) and reminds investors of the November 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

A securities class action chronicles how Ardelyx allegedly reaffirmed billion-dollar sales targets for IBSRELA and XPHOZAH across 19 months while payer prior authorization and step edit barriers were allegedly slowing new-patient starts. NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Ardelyx, Inc. (NASDAQ: ARDX) securities that a securities class action is pending on behalf of shareholders who acquired shares between January 13, 2025 and August 6, 2026.

Ardelyx reported third-quarter product revenue of $125.5 million. Full-year IBSRELA revenue guidance remains $350 million to $370 million.

Ardelyx is upgraded to 'Hold' after a 40% stock decline, despite no fundamental change in its story. IBSRELA drives growth, but SG&A intensity, limited XPHOZAH contribution, and tenapanor concentration constrain upside. DCF model yields a $4.90/share valuation, but 72.6% of the value depends on uncertain terminal assumptions beyond 2034.